Gene · 133396
IL31RA: interleukin 31 receptor A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IL31RA: interleukin 31 receptor A. Genes, record 133396. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/133396
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q8NI17 | Interleukin-31 receptor subunit alpha | 732 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents71
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 67434 | Q8NI17 | Espacenet |
| EP 4644424 A2 | 2025-11-05 | 2 | Q8NI17 | Espacenet |
| EP 4633648 A1 | 2025-10-22 | 42 | Q8NI17 | Espacenet |
| JP 2025530773 A | 2025-09-17 | 2 | Q8NI17 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2099 | Q8NI17 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6733 | Q8NI17 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2099 | Q8NI17 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6733 | Q8NI17 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 67434 | Q8NI17 | Espacenet |
| EP 4547223 A2 | 2025-05-07 | 20 | Q8NI17 | Espacenet |
1 to 10 of 71
See all 71 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| NEMOLIZUMAB | CHEMBL4297794 | Interleukin-31 receptor subunit alpha inhibitor | INHIBITOR |
Source ChEMBL
Trials18
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07074977 | NEMOLIZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07047690 | NEMOLIZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT05214794 | NEMOLIZUMAB | PHASE2 | 2026-02-13 | ClinicalTrials.gov |
| NCT05075408 | NEMOLIZUMAB | PHASE2/PHASE3 | 2025-02-20 | ClinicalTrials.gov |
| NCT05056779 | NEMOLIZUMAB | PHASE3 | ClinicalTrials.gov | |
| NCT05052983 | NEMOLIZUMAB | PHASE3 | 2024-10-08 | ClinicalTrials.gov |
| NCT04921345 | NEMOLIZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT04501679 | NEMOLIZUMAB | PHASE3 | 2024-07-10 | ClinicalTrials.gov |
| NCT04501666 | NEMOLIZUMAB | PHASE3 | 2024-07-10 | ClinicalTrials.gov |
| NCT04204616 | NEMOLIZUMAB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsNIH grants1,599
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IL31RA papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 27 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 12 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 6 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 6 | 2025 |
| ZIAAI005022 | Antibody Neutralization Mechanisms | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 5 | 2025 |
| R35GM136250 | Regulation of cell proliferation by CRL ubiquitin ligases | 5 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 4 | 2025 |
1 to 10 of 1,599Source NIH's project files
See all 1,599 nih grantsPapers2,998
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Off-Label Uses of Nemolizumab: A Narrative Review. | J Drugs Dermatol | 2026 | 42826149 | PubTator, text mining | PubMed |
| Rapid Improvement of Refractory Pruritus in Extragenital and Perianal Lichen Sclerosus With Nemolizumab: A Case Report. | Cureus | 2026 | 42799185 | PubTator, text mining | PubMed |
| SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer. | Nat Commun | 2026 | 42778578 | PubTator, text mining | PubMed |
| Decoding MOF-Enzyme-Substrate Compatibility for Universal Biocatalyst Immobilization. | ACS Appl Mater Interfaces | 2026 | 42742227 | PubTator, text mining | PubMed |
| : Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab. | J Drugs Dermatol | 2026 | 42696343 | PubTator, text mining | PubMed |
| Tape Strip Transcriptomics Reveal Nemolizumab Effects on Pruritus, Hyperplasia, Inflammation, and Extracellular Matrix Markers in Patients With Moderate-to-Severe Atopic Dermatitis. | Allergy | 2026 | 42693785 | PubTator, text mining | PubMed |
| Autosomal recessive OSMRβ deficiency: Connecting OSM and/or IL-31 with atopy. | J Hum Immun | 2026 | 42639505 | PubTator, text mining | PubMed |
| Cryo-EM structure of the interleukin-31 receptor complex defines non-canonical interactions that confer receptor specificity. | J Biol Chem | 2026 | 42637078 | PubTator, text mining | PubMed |
| Impact of IL31RA Genetic Variants and Expression on Metastatic Progression in Oral Cavity Squamous Cell Carcinoma. | Oncol Res | 2026 | 42630481 | PubTator, text mining | PubMed |
| Beyond Histamine: Mast Cell-Neuron Communication in Chronic Pruritic and Pain Disorders. | Exp Dermatol | 2026 | 42619475 | PubTator, text mining | PubMed |
1 to 10 of 2,998
See all 2,998 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/133396
GET https://conductscience.org/api/genes/v1/133396/patents?page=2